BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Applied DNA Sciences, Inc. (APDN) Expands Plant and Personnel


8/7/2012 9:54:27 AM

STONY BROOK, NY--(Marketwire - August 07, 2012) - Applied DNA Sciences, Inc. (OTCBB: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that it has significantly expanded its office, production, and laboratory space and increased its personnel. The expansion reflects the company's continued worldwide growth in production capacity, technology advancement, and global customer support. Those factors are also seen in a steady rise in shipments of its DNA products, the core technology around which the company's authentication services are built.

The company's brick-and-mortar footprint has increased by well over 50% over the last year. The company has added nine positions in that time.

Dr. James A. Hayward, President and CEO of APDN, pointed out that the expansion has been driven in part by product shipments. "By the end of December, 2011, we recorded a substantial increase in our monthly shipments of DNA; as a result, our last two previously announced quarters were each record-setters. Incremental demand should be sustained as new opportunities are addressed."

Dr. Hayward concluded: "In addition to the current growth we are experiencing across the firm, our LMI-managed microchip project is leading the DOD's Defense Logistics Agency to seriously consider mandating SigNature® DNA for microcircuits. We are confident we can support a DOD mandate and continue to source additional candidates as this effort might expand.

"In addition, the initial responses to our new product lines, smartDNA® and digitalDNA™, have been encouraging. Our management team felt it appropriate to grow our resources at this time."

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.


INVESTOR CONTACT:
Debbie Bailey
631-444-8090
fax: 631-444-8848

MEDIA CONTACT:
Mitchell Miller
646-543-3373
fax: 631-444-8848
FCMN Contact: Email Contact
Web site: http://www.adnas.com
Twitter: @APDN, @APDNInvestor



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES